lobbying_activities: 1341558

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1341558	82824ec3-a6d4-4527-8909-fca9cdd9522d	Q4	APOTEX CORP.	310973	APOTEX CORP.	2012	fourth_quarter	PHA	S. 1882, The Fair and Immediate Release of Generics Act S. 27, The Preserve Access to Affordable Pharmaceuticals Act Actelion Pharmaceutical LTD and Actelion Clinical Research Inc. V. Apotex Inc., Apotex Corp., and Roxane Laboratories Inc. The use of Risk Evaluation and Mitigation Strategies (REMS) by brand drug companies to delay generic competition Establishment of a federal track and trace system for pharmaceuticals Adoption of an electronic labeling system for pharmaceuticals	HOUSE OF REPRESENTATIVES,SENATE		90000	0	0	2013-01-18T09:33:42.217000-05:00